CAM HSBIOTECH

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02552

02659

03069

Yesterday, HUA MEDICINE-B triggered a golden cross signal on the daily MACD zero axis in the Hong Kong stock market, with a trading volume of approximately HKD 4.68 million, which is considered a normal high level for this unprofitable biotech stock. The confirmation of the golden cross above the zero axis on the MACD indicates that a medium-term bullish pattern is beginning to take shape, and buying pressure is accumulating in stages. HUA MEDICINE focuses on the research and development of innovative drugs for diabetes, and its stock price has gradually rebounded from a state of extreme sluggishness, with initial signs of a bottom forming. On the news front, the overall biotech sector in the Hong Kong stock market has recently stabilized after a decline. The news that BAO PHARMA has been included in the MSCI Global Small Cap Index has attracted market attention, indicating a renewed recognition of the value of innovative pharmaceutical companies by international capital. The trading activity of the group of Hong Kong 18A biotech companies has recently increased, with some stocks experiencing unusual capital movements. In addition, frequent mergers and acquisitions in the global pharmaceutical industry have heightened market attention to the pipeline value of unprofitable biotech companies, which could serve as a potential catalyst for R&D-focused pharmaceutical companies like HUA MEDICINE. From a technical perspective, HUA MEDICINE-B has limited liquidity, with a low average daily trading volume, so the reference value of technical signals needs to be assessed in conjunction with changes in trading volume. If the trading volume can maintain above HKD 4 million in subsequent trading days and is accompanied by a positive closing price, the reliability of the signal will be enhanced. The overall trend of the biotech sector and the capital flow of similar 18A stocks are important references. The short-term trend is biased towards bullish but should be approached with caution, as technical signals for small-cap, low-liquidity stocks can easily be distorted by large single orders. Attention should be paid to the company's pipeline progress and changes in sector sentiment

Technical Forecast

HUA MEDICINE-B

BAO PHARMA-B

Pre-market trend | HUA MEDICINE-B (2552.HK) Bullish signals emerging on 5/14, is there an undercurrent in innovative small-cap stocks?

516500

159859

588250

513700

513120

159316

510660

159849

The Fifth International Healthcare Week will take place in Hong Kong from May 11 to 31, featuring the Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair. Organized by the HKTDC, the events aim to enhance Hong Kong's role as a medical technology and investment hub, focusing on biopharmaceuticals, AI healthcare, and traditional Chinese medicine. The summit will include discussions on pandemic preparedness and healthcare breakthroughs, with participation from international health officials and industry experts.

Asian Corporate Newswire

ChinaAMC CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

Hwabao WP CSI Hong Kong Connect Medical Treatment Thematic ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Hong Kong Connect Medical Treatment Thematic ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI Biotechnology Theme ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Minsheng Royal CSI Biotechnology Theme ETF

The Fifth International Healthcare Week set for next month, to highlight Hong Kong's position as medical technology and investment hub

09926

159506

The overseas expansion of innovative drugs continues to thrive, with the transaction value of China's innovative drug licensing exceeding USD 60 billion in the first quarter of 2026. The pharmaceutical sector performed strongly, with the Hang Seng Biotech Index rising by 3.21%. Related ETFs also saw significant increases, with notable gains in constituent stocks such as Sanofi and AKESO. Huayuan Securities and Kaiyuan Securities are both optimistic about the long-term development potential of the innovative drug industry chain and related emerging industries, suggesting attention to investment opportunities in these areas

腾讯新闻 - 财经

AKESO

First Trust NYSE Arca Biotech Index Fd

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CSI Biotechnology Theme Index Initiating Fund(LOF)-A

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai Hang Seng Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

3SBIO

INNOVENT BIO

DUALITYBIO-B

SKB BIO

JIANGSU HORIZON

Huaan CNI Biomedicine ETF

Huaan CSI Subdivision Medicine ETF

Sunshine Guojian Pharmaceutical

The explosion of innovative drugs going overseas! In the first quarter, the BD transaction amount exceeded 60 billion USD

588860

On April 1st, the Chinese innovative drug sector experienced an explosion, with the Hong Kong innovative drug ETF index rising over 7%. Three favorable factors drove market sentiment: the implementation of the long-term care insurance system, the upcoming American Association for Cancer Research annual meeting, and the expected FDA approval decision from WuXi AppTec. The trend of Chinese innovative drugs going overseas is evident, with increased attention from the capital market, and it is expected that the total amount of outbound licensing transactions will reach USD 135 billion by 2025, having already surpassed USD 60 billion in the first three months of 2026

WUXI APPTEC

Invesco Great Wall CSI Hong Kong Connect Innovative Drug ETF

WUXI XDC

Yinhua CNI HK Connect Innovative Drugs ETF

WuXi AppTec

Hwabao WP CSI Pharmaceuticals ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Yinhua CSI Innovative Drugs Industry ETF

This sector has gone completely crazy! China's innovative drugs are ushering in a golden era!

As of March 24, the pharmaceutical sector has risen against the trend, with several companies such as KEYMED BIO-B and INSILICO showing significant gains. The industry is overall driven by dual engines of CXO pharmaceutical outsourcing services and ADC antibody-drug conjugates, with leading companies maintaining high performance and a stable policy environment. WuXi AppTec expects double-digit revenue growth by 2025, with ADC innovative drugs gradually entering the harvest period, increasing industry concentration, and deepening the competitive moat of leading enterprises. Investors may focus on ETFs in the biotechnology and innovative drug sectors

VanEck Biotech ETF

ALPS Medical Breakthrough

KEYMED BIO-B

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

China Southern CNI HK Connect Innovative Drug ETF

EFUND BIOPHAR ETF

GX CN BIOTECH

INSILICO

Direxion S&P Biotech Bull 3X

CAM HSBIOTECH-R

WUXI BIO

Harvest CSI Hong Kong Connect Innovative Drugs ETF

Ark Genomic Revolution ETF

WuXi Biologics

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

CCB Principal CSI Innovative Drugs Industry ETF

SPDR S&P Biotech

iShares US Pharma

The performance of leading pharmaceutical companies continues to validate high prosperity, highlighting the undervalued allocation value of the pharmaceutical and biotechnology sector

STECH

03174

09069

The China Securities Regulatory Commission released a quarterly report, indicating that Hong Kong's total IPO fundraising exceeded HKD 280 billion last year, ranking first in the world. Since the launch of the special line for technology companies in May last year, 119 applications from unprofitable biotechnology and specialized technology companies have been received. Last year, the average daily trading volume of the Hong Kong Stock Connect increased by 151%, with a cumulative net inflow of over HKD 5.1 trillion. In terms of digital assets, the managed assets of tokenized retail money market funds grew to HKD 8.66 billion, and the total market value of ETFs increased to HKD 618.7 billion. The net inflow of registered funds in Hong Kong grew by 118.5%

AASTOCKS

Hang Seng TECH Index

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

GX HS TECH

CSOP HEALTHCARE

Huatai-PB Hang Seng Biotech ETF

CAM HS TECH-R

CAM HS TECH-U

ISHARESHSTECH

China Universal Hang Seng Technology ETF(QDII)

CAM HS TECH

CAM HSBIOTECH-U

CSOP HS TECH

CSRC: The special line for science and technology enterprises received 119 applications from unprofitable biotechnology and specialized technology companies last year

The Financial Secretary of the Hong Kong Special Administrative Region, Paul Chan, announced in the budget for the fiscal year 2026 to 2027 that an "International Clinical Trials Academy" will be established next year. The academy aims to promote the introduction and export of national biomedicine technology, helping Hong Kong become a center for international medical innovation

Wallstreetcn

Chen Maobo: The International Clinical Trials Academy will be established next year

03115

00HSI

The Hong Kong Hang Seng Index fell 2% intraday, and the Hang Seng Biotech Index dropped 4%

ISHARESHSI

Hang Seng Index

The Hang Seng Index Company plans to expand its biotechnology index product ecosystem. CEO Wu Wanwen pointed out that the Hang Seng Index performed excellently last year, with an annual increase of 27.8%. In the future, it will strengthen the market leadership of the technology and biotechnology sectors and expand the scale of related asset management. The biotechnology index rose 8.8% this January, surpassing the 7.4% increase of the Hang Seng Composite Index. The company will continue to develop more derivative products to support the development of the healthcare industry

The Hang Seng Index Company plans to expand its biotechnology index product ecosystem

CAM HSBIOTECH(03069.HK)